Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0482 Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT03918278Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of rolistobart in solid tumor (advanced stage), triple-negative breast cancer (TNBC), glioblastoma (GBM) and 3 more (7 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicity, Adverse Events up to 27 months and 1 more. Started Jun 2019; status: completed.
02
Drugs
rolistobart
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)glioblastoma (GBM)pancreatic ductal adenocarcinoma (PDAC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03918278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918278.